EMV Capital plc

We have exciting news to share. NetScientific PLC has officially rebranded to EMV Capital plc from today. This new identity marks a significant milestone in our journey to be a leading VC investor and fund manager in deep tech and lifesciences. Our rebrand reflects our ongoing commitment to generating superior returns for investors from the fast-growing sectors and technologies that will define our future. To note, as a part of our name change, our stock ticker will change from NSCI to EMVC. Visit our website emvcapital.com to explore our unified news page, portfolio and learn about our investment strategy. The full announcement can be found here: https://lnkd.in/dvxNkqz5. To listen to our CEO, ILIAN ILIEV talk about our rebrand, click here: https://lnkd.in/djb4Y2zH. Thank you to our clients, investors, portfolio companies, team members and all our partners for their support on our journey. We look forward to continuing to work together as we embark on this new chapter. #VentureCapital #Growth #EMVC #Deeptech #Lifesciences #AIM #EIS #smallcaps

Well done to the IMPULSE PARTNERS - A FAST LANE FOR INNOVATION team for organising a valuable event last week, showcasing a selection of promising startups in the Construction Tech space and facilitating important connections within the industry, with EMV Capital’s Harry Miller in attendance. EMV Capital already has a footprint in Construction tech, including portfolio companies in robotics, heat pumps, smart buildings and other areas. We believe the scope for innovation in the construction industry is tremendous, and new technologies will play a key role in a more sustainable built environment. #Innovation #VentureCapital #BuiltEnvironment #Startups #DigitalConstruction

Excited to share that our portfolio company Cytovale announced $100M in Series D funding to help hospitals see #sepsis and save lives. Every year, over 1.7 million Americans will experience sepsis and Cytovale has developed the first rapid lab test for sepsis that has been cleared by the FDA, called IntelliSep. Read more in Forbes here: https://lnkd.in/dMtPX9gT  #Lifesciences #VentureCapital #InnovationInHealthcare #Savinglives

An inspiring evening discussing, “Investing in the UK’s university spinouts – the world leading businesses of tomorrow” hosted by Cambridge Innovation Capital, Oxford Science Enterprises and Northern Gritstone last week, with CEO ILIAN ILIEV attending. Presentations from CEOs and founders of companies in the life sciences, health tech and deeptech sectors; all our areas of interest. We were especially impressed by Salience Labs and Optalysys. Since 2014 UK spin-out investment has soared from £1B to £5B, second only to the US. A powerful comment by Sir Nicholas Lyons: “A single UK trillion-pound company would transform the economy and the country.” #Universityspinouts #Cambridge #VentureCapital #Lifesciences #Deeptech

London alone aims to save 126,000 tonnes of Co2 per year by 2025 through waste reduction and recycling initiatives. Go visit our portfolio company, DeepTech Recycling next week at the Recycling Expo to hear about how their innovative technology transforms hard-to-recycle plastic waste into high-value, on demand products, helping us build a greener future. 

Glycotest CEO Charles Swindell discusses the Company’s recently announced partnership with the University of Georgia Complex Carbohydrate Research Center and final steps toward market launch of the HCC Panel test for early-stage liver cancer with Proactive's Stephen Gunnion.  Swindell described the importance of this collaboration for completing the HCC Panel commercial platform to make this potentially important liver cancer detection tool available to the patients at risk and the physicians who care for them. Watch at:  https://lnkd.in/eVBqRJsQ.

Our CEO ILIAN ILIEV presented our Interim Results for the year ended 30 June 2024 to AIM investors at Investor Meet Company. To watch the results presentation and hear about the progress we have made this period, click here: https://lnkd.in/d-39jJkc #AIM #Smallcaps #Growth #Deeptech #Lifesciences #EIS #Venturecapital

Thank you, very exciting to be nominated.

Our portfolio company, PDS Biotechnology (Nasdaq: PDSB), a late-stage immunotherapy company, has announced a 36-month overall survival rate of 84.4% in locally advanced cervical cancer patients treated with Versamune® HPV and chemoradiation. Ann Klopp, M.D., Ph.D., Professor of Radiation Oncology and Head of the Gynecologic Section at MD Anderson said:   “HPV is responsible for virtually all cervical cancers and presents an opportunity for immunologic targeting.1 However, there are currently no FDA-approved HPV-targeted immunotherapies to treat cervical cancer. These data suggest that further investigation is warranted into the safety and efficacy of Versamune® HPV in combination with standard of care in the treatment of locally advanced cervical cancer.”   Read the full release here: https://lnkd.in/djZZ7FdT #AIM #Smallcaps #Growth #Lifesciences #Venturecapital #Oncology #Cancer

CEO ILIAN ILIEV spoke to Proactive about our Interim Results, what this period has brought, and our goal of becoming a leading deeptech and lifesciences VC investor. “Today we are at just over £100M [total AUM], for us the next milestone is £200M plus.” Click here to watch: https://lnkd.in/dridFyTa #AIM #Smallcaps #Growth #Deeptech #Lifesciences #EIS #Venturecapital